CN1898240B
(zh)
*
|
2003-10-15 |
2011-08-03 |
Osi制药公司 |
咪唑并吡嗪类酪氨酸激酶抑制剂
|
WO2005047289A1
(en)
*
|
2003-11-17 |
2005-05-26 |
Pfizer Products Inc. |
Pyrrolopyrimidine compounds useful in treatment of cancer
|
BRPI0509576A
(pt)
|
2004-04-02 |
2007-05-29 |
Osi Pharm Inc |
composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
|
WO2005116035A1
(en)
*
|
2004-05-27 |
2005-12-08 |
Pfizer Products Inc. |
Pyrrolopyrimidine derivatives useful in cancer treatment
|
TW200613306A
(en)
*
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
PL1858877T3
(pl)
|
2005-01-14 |
2014-08-29 |
Gilead Connecticut Inc |
1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
|
US20070287719A1
(en)
*
|
2005-03-11 |
2007-12-13 |
Pfizer Inc |
Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
|
US7777040B2
(en)
|
2005-05-03 |
2010-08-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
US7795248B2
(en)
*
|
2005-05-18 |
2010-09-14 |
Abbott Laboratories, Inc. |
Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors
|
DE102005037499A1
(de)
*
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
WO2007024754A1
(en)
*
|
2005-08-22 |
2007-03-01 |
Amgen Inc. |
Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes
|
US8592433B2
(en)
*
|
2005-10-28 |
2013-11-26 |
Advait Nagle |
Compounds and compositions as protein kinase inhibitors
|
EP2385053B1
(en)
*
|
2005-11-17 |
2013-10-02 |
OSI Pharmaceuticals, Inc. |
Intermediates for the preparation of fused bicyclic mTOR inhibitors
|
US20070135387A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Michaelides Michael R |
Inhibitors of protein kinases
|
WO2007066189A2
(en)
*
|
2005-12-09 |
2007-06-14 |
Pfizer Products Inc. |
Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
|
JP2009520028A
(ja)
*
|
2005-12-19 |
2009-05-21 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
Igfr抑制剤および抗癌剤の併用
|
US8575164B2
(en)
*
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
ES2545907T3
(es)
*
|
2005-12-29 |
2015-09-16 |
Abbvie Inc. |
Inhibidores de proteína quinasa
|
ES2689444T3
(es)
*
|
2006-11-22 |
2018-11-14 |
Incyte Holdings Corporation |
Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
WO2008076143A1
(en)
*
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
EP2170830B1
(en)
|
2007-07-17 |
2014-10-15 |
Plexxikon, Inc. |
2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
US20100331297A1
(en)
*
|
2007-11-07 |
2010-12-30 |
Foldrx Pharmaceuticals, Inc. |
Modulation of protein trafficking
|
WO2009091939A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Osi Pharmaceuticals, Inc. |
Imidazopyrazinol derivatives for the treatment of cancers
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
JP2011520970A
(ja)
*
|
2008-05-19 |
2011-07-21 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
置換されたイミダゾピラジン類およびイミダゾトリアジン類
|
PE20091846A1
(es)
*
|
2008-05-19 |
2009-12-16 |
Plexxikon Inc |
DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
|
AU2009257635A1
(en)
*
|
2008-06-10 |
2009-12-17 |
Plexxikon, Inc. |
5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
|
WO2009152087A1
(en)
*
|
2008-06-10 |
2009-12-17 |
Plexxikon, Inc. |
Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
ES2570429T3
(es)
*
|
2008-10-16 |
2016-05-18 |
Univ California |
Inhibidores de heteroaril quinasa de anillo condensado
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
EP2408479A1
(en)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
MY172424A
(en)
|
2009-04-03 |
2019-11-25 |
Hoffmann La Roche |
Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
|
CA2752826A1
(en)
|
2009-04-20 |
2010-10-28 |
OSI Pharmaceuticals, LLC |
Preparation of c-pyrazine-methylamines
|
JP2012526138A
(ja)
*
|
2009-05-07 |
2012-10-25 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
副腎皮質癌を治療するためのosi−906の使用
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
MX2012002066A
(es)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Compuestos heterociclicos y usos de los mismos.
|
BR112012003462A2
(pt)
|
2009-08-24 |
2016-02-23 |
Ascepion Pharmaceuticals Inc |
"composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
|
BR112012012156A2
(pt)
|
2009-11-06 |
2015-09-08 |
Plexxikon Inc |
compostos e métodos para modulação de cinase, e indicações para esta
|
ES2627911T3
(es)
*
|
2009-11-18 |
2017-08-01 |
Plexxikon, Inc. |
Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
CN102892768A
(zh)
|
2009-12-30 |
2013-01-23 |
艾科尔公司 |
被取代的吡咯并氨基嘧啶化合物
|
WO2011153553A2
(en)
|
2010-06-04 |
2011-12-08 |
The Regents Of The University Of California |
Methods and compositions for kinase inhibition
|
US10420665B2
(en)
|
2010-06-13 |
2019-09-24 |
W. L. Gore & Associates, Inc. |
Intragastric device for treating obesity
|
US9526648B2
(en)
|
2010-06-13 |
2016-12-27 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
US10010439B2
(en)
|
2010-06-13 |
2018-07-03 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
US8628554B2
(en)
|
2010-06-13 |
2014-01-14 |
Virender K. Sharma |
Intragastric device for treating obesity
|
WO2012064744A2
(en)
*
|
2010-11-08 |
2012-05-18 |
Lycera Corporation |
Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
TR201816421T4
(tr)
|
2011-02-07 |
2018-11-21 |
Plexxikon Inc |
Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
UA108926C2
(ru)
|
2011-04-05 |
2015-06-25 |
Пфайзер Лімітед |
LibreOffice? [2,3-D] +" +" !+
|
KR20140048968A
(ko)
*
|
2011-07-13 |
2014-04-24 |
파마시클릭스, 인코포레이티드 |
브루톤형 티로신 키나제의 억제제
|
WO2013032951A1
(en)
|
2011-08-26 |
2013-03-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
JP6093768B2
(ja)
|
2011-09-14 |
2017-03-08 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
BR112014018450A8
(pt)
*
|
2012-01-25 |
2017-07-11 |
Bayer Ip Gmbh |
Fenilimidazopirazoles substituídos e sua utilização
|
US9394315B2
(en)
|
2012-05-08 |
2016-07-19 |
Lycera Corporation |
Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
US9657033B2
(en)
|
2012-05-08 |
2017-05-23 |
Lycera Corporation |
Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
ME03300B
(me)
|
2012-06-13 |
2019-07-20 |
Incyte Holdings Corp |
Supsтituisana triciklična jedinjenja као inhibiтori fgfr
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
WO2014047648A1
(en)
|
2012-09-24 |
2014-03-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ire1の調節
|
EP2903989A1
(en)
|
2012-10-04 |
2015-08-12 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
EP2903986A1
(en)
|
2012-10-04 |
2015-08-12 |
Pfizer Limited |
Tropomyosin-related kinase inhibitors
|
JP2015531395A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤
|
EP2916838B1
(en)
|
2012-11-12 |
2019-03-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
WO2014153509A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
DK2986610T5
(en)
|
2013-04-19 |
2018-12-10 |
Incyte Holdings Corp |
BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
US9809561B2
(en)
|
2013-12-20 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
CA2934010A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
US9783511B2
(en)
|
2013-12-20 |
2017-10-10 |
Lycera Corporation |
Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
|
US9663502B2
(en)
|
2013-12-20 |
2017-05-30 |
Lycera Corporation |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
|
CN106132422A
(zh)
|
2014-02-27 |
2016-11-16 |
莱斯拉公司 |
使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法
|
EP3131891A1
(en)
|
2014-04-15 |
2017-02-22 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
|
EP3209641A4
(en)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
|
AU2015256190B2
(en)
|
2014-05-05 |
2019-08-15 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
CN107108631B
(zh)
|
2014-11-14 |
2020-06-16 |
内尔维阿诺医学科学有限公司 |
作为蛋白激酶抑制剂的6-氨基-7-二环-7-脱氮-嘌呤衍生物
|
JP2018510135A
(ja)
|
2015-02-11 |
2018-04-12 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
RORγT阻害剤としての置換ピラゾール化合物及びその使用
|
EA038045B1
(ru)
|
2015-02-20 |
2021-06-28 |
Инсайт Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
JP6793401B2
(ja)
*
|
2015-03-11 |
2020-12-02 |
国立研究開発法人理化学研究所 |
難治性白血病治療薬
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
MA41559A
(fr)
|
2015-09-08 |
2017-12-26 |
Taiho Pharmaceutical Co Ltd |
Composé de pyrimidine condensé ou un sel de celui-ci
|
EP3368535B1
(en)
|
2015-10-27 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
EP3368539B1
(en)
|
2015-10-27 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Substituted indazole compounds as ror gamma t inhibitors and uses thereof
|
WO2017075178A1
(en)
|
2015-10-27 |
2017-05-04 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
KR20180094940A
(ko)
*
|
2015-12-02 |
2018-08-24 |
아스트레아 테라퓨틱스 엘엘씨 |
피페리디닐 노시셉틴 수용체 화합물
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
US9630968B1
(en)
|
2015-12-23 |
2017-04-25 |
Arqule, Inc. |
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
WO2017133669A1
(en)
*
|
2016-02-05 |
2017-08-10 |
Savira Pharmaceuticals Gmbh |
5, 7-diazaindole and 5, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
|
PT3269370T
(pt)
|
2016-02-23 |
2020-03-05 |
Taiho Pharmaceutical Co Ltd |
Novo composto de pirimidina condensada ou sal do mesmo
|
US10779980B2
(en)
|
2016-04-27 |
2020-09-22 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
CN110461849B
(zh)
*
|
2017-06-19 |
2020-09-01 |
上海和誉生物医药科技有限公司 |
一种csf1r抑制剂及其制备方法和应用
|
WO2019036001A1
(en)
*
|
2017-08-17 |
2019-02-21 |
Vyera Pharmaceuticals, LLC |
CDPK1 INHIBITOR, COMPOSITIONS AND RELATED METHODS
|
US11466004B2
(en)
|
2018-05-04 |
2022-10-11 |
Incyte Corporation |
Solid forms of an FGFR inhibitor and processes for preparing the same
|
EA202092649A1
(ru)
|
2018-05-04 |
2021-06-21 |
Инсайт Корпорейшн |
Соли ингибитора fgfr
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
IL291901A
(en)
|
2019-10-14 |
2022-06-01 |
Incyte Corp |
Bicyclyl heterocycles as fgr suppressors
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
KR20220131900A
(ko)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Fgfr 억제제의 유도체
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CN112574200B
(zh)
|
2021-02-26 |
2021-06-11 |
安润医药科技(苏州)有限公司 |
Btk和/或btk的突变体c481s的小分子抑制剂
|
AR126102A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|